Bryan, Garnier & Co Reiterates Buy Rating for GlaxoSmithKline plc (GSK)
GlaxoSmithKline plc (LON:GSK)‘s stock had its “buy” rating reiterated by Bryan, Garnier & Co in a report released on Monday.
GSK has been the topic of a number of other reports. Societe Generale lowered shares of GlaxoSmithKline plc to a “sell” rating and increased their price objective for the stock from GBX 1,300 ($16.09) to GBX 1,320 ($16.34) in a research report on Thursday, September 8th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a GBX 1,900 ($23.51) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, August 23rd. BNP Paribas reissued an “underperform” rating and issued a GBX 1,520 ($18.81) price objective on shares of GlaxoSmithKline plc in a research report on Friday, September 30th. Deutsche Bank AG reissued a “hold” rating and issued a GBX 1,870 ($23.14) price objective on shares of GlaxoSmithKline plc in a research report on Wednesday, October 12th. Finally, Liberum Capital reissued a “buy” rating and issued a GBX 1,900 ($23.51) price objective on shares of GlaxoSmithKline plc in a research report on Tuesday, September 20th. Three analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,687.13 ($20.88).
GlaxoSmithKline plc (LON:GSK) opened at 1685.24 on Monday. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56. The stock’s 50 day moving average price is GBX 1,650.69 and its 200-day moving average price is GBX 1,561.99. The firm’s market cap is GBX 81.92 billion.
The firm also recently announced a dividend, which was paid on Thursday, October 13th. Investors of record on Thursday, August 11th were issued a dividend of GBX 19 ($0.24) per share. The ex-dividend date was Thursday, August 11th. This represents a dividend yield of 1.12%.
In related news, insider Witty,Sir Andrew P sold 10,000 shares of the firm’s stock in a transaction on Wednesday, July 27th. The shares were sold at an average price of GBX 1,693 ($20.95), for a total transaction of £169,300 ($209,529.70). Also, insider Slaoui,Moncef bought 28 shares of GlaxoSmithKline plc stock in a transaction that occurred on Friday, August 12th. The shares were acquired at an average cost of GBX 2,208 ($27.33) per share, with a total value of £618.24 ($765.15).
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.